ABT-239 is an
H3-receptor inverse agonist developed by
Abbott. It has
stimulant and
nootropic
Nootropics ( , or ) (colloquial: smart drugs and cognitive enhancers, similar to adaptogens) are a wide range of natural or synthetic dietary supplement, supplements or drugs and other substances that are claimed to improve cognitive function ...
effects, and has been investigated as a treatment for
ADHD,
Alzheimer's disease, and
schizophrenia
Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking. Other symptoms include social wit ...
.
ABT-239 is more active at the human H
3 receptor than comparable agents such as
thioperamide,
ciproxifan, and
cipralisant
Cipralisant (GT-2331, tentative trade name Perceptin) is an extremely potent histamine H3 receptor ligand originally developed by Gliatech. Cipralisant was initially classified as a selective H3 antagonist, but newer research (2005) suggests a ...
. It was ultimately dropped from human trials after showing the dangerous cardiac side effect of
QT prolongation
Long QT syndrome (LQTS) is a condition affecting repolarization (relaxing) of the heart after a heartbeat, giving rise to an abnormally lengthy QT interval. It results in an increased risk of an irregular heartbeat which can result in fainting ...
,
but is still widely used in animal research into H
3 antagonists / inverse agonists.
References
External links
*
Nootropics
H3 receptor antagonists
Benzonitriles
Benzofuranethanamines
Pyrrolidines
Biphenyls
{{nervous-system-drug-stub